• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于机器学习的整合揭示了肝细胞癌中免疫异质性及T细胞受体(TCR)基因模式的临床潜力。

Machine learning-based integration reveals immunological heterogeneity and the clinical potential of T cell receptor (TCR) gene pattern in hepatocellular carcinoma.

作者信息

Zhuo Zewei, Wu Huihuan, Xu Lingli, Ji Yuran, Li Jiezhuang, Liu Liehui, Zhang Hong, Yang Qi, Zheng Zhongwen, Lun Weijian

机构信息

School of Medicine, South China University of Technology, Guangzhou, 510006, China.

Department of Gastroenterology, The Sixth Affiliated Hospital, South China University of Technology, Foshan, 510315, China.

出版信息

Apoptosis. 2025 Apr;30(3-4):955-975. doi: 10.1007/s10495-025-02080-6. Epub 2025 Feb 4.

DOI:10.1007/s10495-025-02080-6
PMID:39904860
Abstract

The T Cell Receptor (TCR) significantly contributes to tumor immunity, whereas the intricate interplay with the Hepatocellular Carcinoma (HCC) microenvironment and clinical significance remains largely unexplored. Here, we aimed to examine the function of TCR signaling in tumor immunity and its clinical significance in HCC. Our objective was to employ TCR signaling genes and a machine learning-based integrative methodology to construct a prognostic prediction system termed the TCR score. Herein, we revealed that the TCR score serves as an independent risk factor for overall survival in HCC patients, demonstrating stable and robust performance. The accuracy of the TCR score significantly exceeds that of traditional clinical variables and published signatures. Additionally, the immune infiltration was abundant in patients with low TCR scores. Single-cell cohort analysis further demonstrates that patients with low TCR scores possess an immune-active tumor microenvironment (TME), with T/NK cells enhancing interactions with myeloid cells through signaling networks such as MIF, MK, and SPP1. In response to these changes in the TME, patients with high TCR scores exhibit poorer outcomes and shorter survival in immunotherapy cohorts. In vitro experiments demonstrated that the key TCR signaling biomarker SOS1 knockdown significantly suppresses the HCC cells' capability to proliferate, invade, and migrate while enhancing tumor cell apoptosis. The TCR score could function as a robust and potential tool to predict immune activity and improve clinical outcomes for HCC patients.

摘要

T细胞受体(TCR)对肿瘤免疫有显著贡献,然而其与肝细胞癌(HCC)微环境的复杂相互作用及临床意义在很大程度上仍未得到充分探索。在此,我们旨在研究TCR信号在肿瘤免疫中的功能及其在HCC中的临床意义。我们的目标是利用TCR信号基因和基于机器学习的整合方法构建一个称为TCR评分的预后预测系统。在此,我们发现TCR评分是HCC患者总生存的独立危险因素,表现出稳定且强大的性能。TCR评分的准确性显著超过传统临床变量和已发表的特征。此外,TCR评分低的患者免疫浸润丰富。单细胞队列分析进一步表明,TCR评分低的患者拥有免疫活性肿瘤微环境(TME),T细胞/自然杀伤细胞(T/NK细胞)通过如巨噬细胞移动抑制因子(MIF)、巨噬细胞趋化因子(MK)和分泌性磷蛋白1(SPP1)等信号网络增强与髓系细胞的相互作用。针对TME的这些变化,TCR评分高的患者在免疫治疗队列中表现出更差的预后和更短的生存期。体外实验表明,关键的TCR信号生物标志物SOS1基因敲低显著抑制HCC细胞的增殖、侵袭和迁移能力,同时增强肿瘤细胞凋亡。TCR评分可作为一种强大且有潜力的工具,用于预测免疫活性并改善HCC患者的临床结局。

相似文献

1
Machine learning-based integration reveals immunological heterogeneity and the clinical potential of T cell receptor (TCR) gene pattern in hepatocellular carcinoma.基于机器学习的整合揭示了肝细胞癌中免疫异质性及T细胞受体(TCR)基因模式的临床潜力。
Apoptosis. 2025 Apr;30(3-4):955-975. doi: 10.1007/s10495-025-02080-6. Epub 2025 Feb 4.
2
Interplay between tumor mutation burden and the tumor microenvironment predicts the prognosis of pan-cancer anti-PD-1/PD-L1 therapy.肿瘤突变负荷与肿瘤微环境之间的相互作用可预测泛癌抗PD-1/PD-L1治疗的预后。
Front Immunol. 2025 Jul 24;16:1557461. doi: 10.3389/fimmu.2025.1557461. eCollection 2025.
3
Multi-omics analysis identifies SNP-associated immune-related signatures by integrating Mendelian randomization and machine learning in hepatocellular carcinoma.多组学分析通过整合孟德尔随机化和机器学习在肝细胞癌中识别与单核苷酸多态性相关的免疫相关特征。
Sci Rep. 2025 Jul 4;15(1):23930. doi: 10.1038/s41598-025-09010-1.
4
Identification of anoikis-related subtypes and a risk score prognosis model, the association with TME landscapes and therapeutic responses in hepatocellular carcinoma.肝细胞癌中失巢凋亡相关亚型的鉴定及风险评分预后模型、与肿瘤微环境景观和治疗反应的关联
Front Immunol. 2025 Jun 17;16:1602831. doi: 10.3389/fimmu.2025.1602831. eCollection 2025.
5
Machine learning developed LKB1-AMPK signaling related signature for prognosis and drug sensitivity in hepatocellular carcinoma.机器学习开发了用于预测肝细胞癌预后和药物敏感性的LKB1-AMPK信号相关特征。
Sci Rep. 2025 Jul 1;15(1):20738. doi: 10.1038/s41598-025-08583-1.
6
Harnessing multi-omics and artificial intelligence: revolutionizing prognosis and treatment in hepatocellular carcinoma.利用多组学和人工智能:革新肝细胞癌的预后和治疗
Front Immunol. 2025 Jul 23;16:1592259. doi: 10.3389/fimmu.2025.1592259. eCollection 2025.
7
The impact of de novo lipogenesis on predicting survival and clinical therapy: an exploration based on a multigene prognostic model in hepatocellular carcinoma.从头脂肪生成对预测生存和临床治疗的影响:基于肝细胞癌多基因预后模型的探索
J Transl Med. 2025 Jun 18;23(1):679. doi: 10.1186/s12967-025-06704-y.
8
Integrative spatial and single-cell transcriptomics elucidate programmed cell death-driven tumor microenvironment dynamics in hepatocellular carcinoma.整合空间转录组学和单细胞转录组学揭示了程序性细胞死亡驱动的肝细胞癌肿瘤微环境动态变化。
Front Immunol. 2025 Jul 16;16:1589563. doi: 10.3389/fimmu.2025.1589563. eCollection 2025.
9
Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma.单细胞RNA测序衍生的特征定义了晚期肝细胞癌对阿替利珠单抗+贝伐单抗的反应模式。
J Hepatol. 2025 Jun;82(6):1036-1049. doi: 10.1016/j.jhep.2024.12.016. Epub 2024 Dec 19.
10
A Novel RNA Methylation-Related Prognostic Signature and its Tumor Microenvironment Characterization in Hepatocellular Carcinoma.新型 RNA 甲基化相关预后标志物及其在肝细胞癌中的肿瘤微环境特征。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241276895. doi: 10.1177/15330338241276895.

本文引用的文献

1
Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors.嵌合抗原受体T细胞(CAR-T)疗法治疗实体瘤的当前挑战与治疗进展
Cancer Cell Int. 2024 Apr 15;24(1):133. doi: 10.1186/s12935-024-03315-3.
2
The recent advancement of TCR-T cell therapies for cancer treatment.TCR-T 细胞疗法在癌症治疗方面的最新进展。
Acta Biochim Biophys Sin (Shanghai). 2024 May 25;56(5):663-674. doi: 10.3724/abbs.2024034.
3
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.晚期肝细胞癌的系统治疗:ASCO 指南更新。
J Clin Oncol. 2024 May 20;42(15):1830-1850. doi: 10.1200/JCO.23.02745. Epub 2024 Mar 19.
4
Role of T cells in cancer immunotherapy: Opportunities and challenges.T细胞在癌症免疫治疗中的作用:机遇与挑战。
Cancer Pathog Ther. 2022 Dec 20;1(2):116-126. doi: 10.1016/j.cpt.2022.12.002. eCollection 2023 Apr.
5
Adverse clinical outcomes and immunosuppressive microenvironment of RHO-GTPase activation pattern in hepatocellular carcinoma.肝癌中 RHO-GTPase 激活模式的不良临床结局和免疫抑制微环境。
J Transl Med. 2024 Jan 31;22(1):122. doi: 10.1186/s12967-024-04926-0.
6
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges.新抗原靶向的TCR工程化T细胞免疫疗法:当前进展与挑战
Biomark Res. 2023 Dec 1;11(1):104. doi: 10.1186/s40364-023-00534-0.
7
Recent advances in recurrent hepatocellular carcinoma therapy.复发性肝细胞癌治疗的最新进展
World J Hepatol. 2023 Apr 27;15(4):460-476. doi: 10.4254/wjh.v15.i4.460.
8
TCR-engineered T cell therapy in solid tumors: State of the art and perspectives.T 细胞受体工程化 T 细胞疗法治疗实体瘤:现状与展望。
Sci Adv. 2023 Feb 15;9(7):eadf3700. doi: 10.1126/sciadv.adf3700.
9
Immunosuppressive role of SPP1-CD44 in the tumor microenvironment of intrahepatic cholangiocarcinoma assessed by single-cell RNA sequencing.单细胞 RNA 测序评估 SPP1-CD44 在肝内胆管癌肿瘤微环境中的免疫抑制作用。
J Cancer Res Clin Oncol. 2023 Aug;149(9):5497-5512. doi: 10.1007/s00432-022-04498-w. Epub 2022 Dec 5.
10
Global burden of primary liver cancer in 2020 and predictions to 2040.2020 年全球原发性肝癌负担及 2040 年预测。
J Hepatol. 2022 Dec;77(6):1598-1606. doi: 10.1016/j.jhep.2022.08.021. Epub 2022 Oct 5.